Skin toxicity and effectiveness of first-line enfortumab vedotin plus pembrolizumab for urothelial carcinoma: a prospective multicenter real-world study in Japan.
Overview & Synopsis
Open access biomedical research article published in ESMO Real World Data Digit Oncol.
Indexed from repository: PubMed Central
(
pmc.ncbi.nlm.nih.gov)
Keyboard Shortcuts:
← / → for pages • + / - for zoom • 0 to fit width
Powered by Mozilla PDF.js v3.11
Document Information
| Document Title | Skin toxicity and effectiveness of first-line enfortumab vedotin plus pembrolizumab for urothelial carcinoma: a prospective multicenter real-world study in Japan. |
|---|---|
| Author / Organization | Tamura K, Tsujino T, Taoka R, Kobayashi K, Miyake M, Ogawa K, Sasaki Y, Tatarano S, Katayama S, Kato M, Fukuhara H, Abe Y, Oda Y, Minato R, Shigehisa R, Maenosono R, Sugimoto M, Shiraishi K, Fujimoto K, Wada K, Furukawa J, Enokida H, Araki M, Uchida J, Inoue K, Inamoto T, West Japan Uro-oncology Collaboration Group |
| Subject & Discipline | ESMO Real World Data Digit Oncol |
| Categories | Medicine & Health |
| Publication Year | 2026 |
| License / Rights | Open Access / Creative Commons |
| Resource Verification | Listed PDF (Verification Pending) |
| Original Host Website |
PubMed Central
(pmc.ncbi.nlm.nih.gov)
|
| File Format | application/pdf (Portable Document Format) |
| Language | EN |
| Catalog ID | DOC-10612 |
| Original Source Link | Visit Source Page on pmc.ncbi.nlm.nih.gov » |